The Negative Effects of Semaglutide: Deciding Whether the Trade-Off Works for You

What most people actually experience, and when it tends to ease

The majority of side effects with semaglutide sit in the gut. Nausea is the most frequently reported, followed by vomiting, diarrhoea and constipation, with indigestion, burping and fatigue also common. These aren't random, semaglutide slows gastric emptying as part of its mechanism, so your stomach takes longer to clear. For most people that's manageable; for a smaller number it's genuinely disruptive, at least initially.

The pattern matters: symptoms tend to be most pronounced in the first one to two weeks at any given dose and usually settle before the next titration step. Eating smaller meals, avoiding very fatty or rich food, and staying properly hydrated all help. Plenty of people describe the early weeks as the hardest part, and then find the medicine much easier to tolerate as their body adjusts.

The NHS patient information for semaglutide lists the full frequency breakdown and explains which symptoms to monitor. It's worth reading alongside the Patient Information Leaflet in your pack, not instead of it. If you want to understand how these effects sit within the broader picture of what semaglutide actually does in the body, that page covers the mechanism and evidence together.

The side-effect profile of the Wegovy injection and the newer oral Wegovy tablet are broadly similar (both deliver semaglutide) though the tablet's OASIS 4 trial reported gastrointestinal events in around 74% of participants versus 42% on placebo, generally described as mild to moderate and transient.

The risks that need more than watchful waiting

Most negative effects of semaglutide are uncomfortable rather than dangerous. A few are not. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but potentially serious risk associated with GLP-1 medicines including semaglutide. The signal to act on: severe, persistent abdominal pain that radiates toward the back, with or without vomiting. That combination needs same-day medical attention, not a wait-and-see approach.

Gallbladder problems are also documented, gallstones and inflammation occur more often in people losing weight rapidly regardless of the method, and semaglutide appears to add a small additional risk. Tell your GP or prescriber if you develop sharp upper-right abdominal pain, especially after eating.

Dehydration is a secondary risk that tends to be underestimated. Prolonged vomiting or diarrhoea at dose increases can reduce fluid intake sharply; in people with certain kidney conditions that can escalate quickly. Keeping fluid up during a difficult GI week is practical advice, not a formality.

Allergic reactions are rare but documented. Swelling of the face, throat or tongue, difficulty breathing, and a rapid heartbeat are signs to treat as urgent. The MHRA's Yellow Card scheme exists precisely so that patients (not just clinicians) can report suspected adverse effects directly, and those reports actively shape how the regulator monitors these medicines post-approval.

Groups for whom the negative effects carry more weight

A clinician's job at the assessment stage is to identify where the risk calculus shifts. Some health histories make semaglutide unsuitable regardless of how well someone tolerates GI side effects. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome puts this medicine in the contraindicated column. A history of pancreatitis or certain gastrointestinal conditions (gastroparesis in particular) requires careful prescriber judgement. These aren't gatekeeping for its own sake; they reflect what the clinical evidence and the SmPC specify.

Pregnancy and breastfeeding are clear exclusions: semaglutide is not recommended for people who are pregnant, nursing, or trying to conceive. For women of childbearing age, the MHRA advises using effective contraception during treatment. Unlike tirzepatide, there's currently no specific evidence that semaglutide reduces the effectiveness of oral contraceptives, but this should still be discussed with a prescriber.

Age is another consideration. Semaglutide is not licensed for use in under-18s. Older adults with existing GI conditions or those on multiple other medicines require a more detailed review of possible interactions. If you're weighing up the negatives of Wegovy specifically in the context of your own health conditions, that page goes into more detail on how those conversations with a prescriber tend to go.

Thinking about the overall picture of how Wegovy affects people across a treatment course can also help frame whether short-term discomfort is likely to be worth tolerating.

What this means for your decision

If you've arrived at this page, you're probably not looking for a sales pitch, you're trying to decide whether this medicine's downsides are ones you can live with. That's the right question to be asking. The documented adverse effects of semaglutide are neither trivial nor catastrophic for most people who meet the clinical criteria; they sit, for the majority, in the category of manageable-with-preparation.

What matters most is that the decision is made with accurate information and clinical oversight, not a rushed checkout. A full overview of semaglutide (including how it works, what trials showed on weight reduction, and how it's used in practice) may help round out what you read here.

The cost of private treatment is a real factor for many people too. If you want to understand what's included in a private prescription and how pricing is structured, the Wegovy pricing page sets that out plainly, without hidden extras to decode.

A prescriber at nume can review your health history, current medicines and circumstances the same day you submit a consultation. No algorithm makes that call, a real clinician reads your answers, checks what the clinical evidence says for your profile, and decides whether treatment is appropriate. That's the only honest way to answer the question this page can't fully answer for you: whether the trade-off is right for you.

If you're ready to get a proper assessment, start your free consultation with our prescribers.